Selected publications from the Essand group

  1. Barbera S, Schuiling MJA, Sanjaya NA, Pietilä I, Sarén T, Essand M*, Dimberg A*. Trogocytosis of Chimeric Antigen Receptors between T cells is regulated by their transmembrane domains. Science Immunology, 10: eado2054, 2025. ME and AD are shared senior authors.
  2. Martikainen M, Lugano R, Pietilä I, Brosch S, Cabrolier C, Sivaramakrishnam A, Ramachandran M, Yu D, Dimberg A, Essand M. VLDLR mediates Semliki Forest virus neuroinvasion through the blood-cerebrospinal fluid barrier. Nature Communications, 15:10718, 2024.
  3. Sarén T#, Ramachandran M#, Gammelgård G, Lövgren T, Mirabello C, Björklund ÅK, Wikström K, Hashemi J, Freyhult E, Ahlström H, Amini R-M, Hagberg H, Loskog A, Enblad G*, Essand M*. Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T-cells correlating with response in a phase II study of lymphoma patients. Clinical Cancer Research, 29:4139, 2023. TS and MR are shared first authors; GE and ME are shared senior authors.
  4. Sarén T, Saronio G, Marti-Torell P, Zhu X, Thelander J, Andersson Y, Hofström C, Nestor M, Dimberg A, Persson H, Ramachandran M, Yu D*, Essand M*. Complementarity-determining region clustering may cause CAR-T cell dysfunction. Nature Communications, 14:4732, 2023. DY and ME are shared senior authors.
  5. Ramachandran M#, Vaccaro A#, van de Walle T#, Georganaki M, Lugano, R, Vemuri, K, Kourougkiaouri D, Vazaios K, Hedlund M, Tsaridou G, Uhrbom L, Pietilä I, Martikainen M, Van Hooren L, Olsson Bontell T, Jakola AS, Yu D, Westermark B, Essand M*, Dimberg A*. Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer Cell, 41:1134, 2023. MR, AV and TwDW are shared first authors; ME and AD are shared senior authors.
  6. Jin C#, Ma J#, Ramachandran M, Yu D*, Essand M*. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nature Biomedical Engineering, 6:830, 2022. CJ and JM are shared first authors; DY and ME are shared senior authors.
  7. Ma J#, Ramachandran M, # Jin C#, Quijano-Rubio, Martikainen M, Yu D*, Essand M*. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death & Disease 11: 48, 2020. JM, MR and CJ are shared first authors; DY and ME are shared senior authors.
  8. Ramachandran M#, Yu D#, Dyczynski M, Baskaran S, Nelander S, Zhang L, Lulla A, Lulla V, Saul S, Dimberg A, Merits A, Leja-Jarblad J, Essand M. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically administered triple microRNA-detargeted oncolytic Semliki Forest virus. Clinical Cancer Research, 23: 1519-1530, 2017. MR and DY are shared first authors.
  9. Jin C, Fotaki G, Ramachandran M, Nilsson B, Essand M*, Yu D*. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer. EMBO Molecular Medicine, 8: 702-11, 2016. ME and DY are shared senior authors.
  10. Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M. TARP-TCR-engineered T cells specifically kill HLA-A2 positive prostate and breast cancer cells. Proc Natl Acad Sci USA, 109:15877-15881, 2012.

Last modified: